ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
4.090
+0.170 (4.34%)
Apr 2, 2025, 11:54 AM EDT - Market open

ENDRA Life Sciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
--10.06-13.18-11.23-11.73
Upgrade
Depreciation & Amortization
-0.280.230.220.17
Upgrade
Other Amortization
----0.23
Upgrade
Asset Writedown & Restructuring Costs
-0.0200.01-
Upgrade
Stock-Based Compensation
-11.21.442.1
Upgrade
Other Operating Activities
-0.14--0.31-
Upgrade
Change in Inventory
--0.12-1.36-0.69-0.48
Upgrade
Change in Accounts Payable
--0.820.110.49-0.83
Upgrade
Change in Other Net Operating Assets
-0.020.22-1.06-0.21
Upgrade
Operating Cash Flow
--9.55-12.77-11.12-10.75
Upgrade
Capital Expenditures
--0.03-0.2-0.05-0.08
Upgrade
Sale of Property, Plant & Equipment
-0.01---
Upgrade
Investing Cash Flow
--0.02-0.2-0.05-0.08
Upgrade
Long-Term Debt Issued
----0.34
Upgrade
Total Debt Issued
----0.34
Upgrade
Net Debt Issued (Repaid)
----0.34
Upgrade
Issuance of Common Stock
-7.58.413.411.54
Upgrade
Other Financing Activities
-0.02---
Upgrade
Financing Cash Flow
-7.528.413.411.88
Upgrade
Net Cash Flow
--2.06-4.572.231.05
Upgrade
Free Cash Flow
--9.58-12.97-11.17-10.82
Upgrade
Cash Interest Paid
-0.040.060.060
Upgrade
Levered Free Cash Flow
--5.86-4.78-6.75-6.39
Upgrade
Unlevered Free Cash Flow
--5.86-4.78-6.75-6.47
Upgrade
Change in Net Working Capital
0.050.52-2.211.181.48
Upgrade
Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q